122 related articles for article (PubMed ID: 19632947)
1. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.
Gualberto A; Karp DD
Clin Lung Cancer; 2009 Jul; 10(4):273-80. PubMed ID: 19632947
[TBL] [Abstract][Full Text] [Related]
2. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P
Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288
[TBL] [Abstract][Full Text] [Related]
3. Figitumumab (CP-751,871) for cancer therapy.
Gualberto A
Expert Opin Biol Ther; 2010 Apr; 10(4):575-85. PubMed ID: 20175655
[TBL] [Abstract][Full Text] [Related]
4. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y; Sekine I; Tanioka M; Shibata T; Tanai C; Asahina H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kikkawa H; Ohki E; Tamura T
Invest New Drugs; 2012 Aug; 30(4):1548-56. PubMed ID: 21748299
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Karp DD; Paz-Ares LG; Novello S; Haluska P; Garland L; Cardenal F; Blakely LJ; Eisenberg PD; Langer CJ; Blumenschein G; Johnson FM; Green S; Gualberto A
J Clin Oncol; 2009 May; 27(15):2516-22. PubMed ID: 19380445
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
[TBL] [Abstract][Full Text] [Related]
9. Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys.
Bowman CJ; Chmielewski G; Oneda S; Finco D; Boucher MA; Todd M
Birth Defects Res B Dev Reprod Toxicol; 2010 Aug; 89(4):326-38. PubMed ID: 20540090
[TBL] [Abstract][Full Text] [Related]
10. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
[TBL] [Abstract][Full Text] [Related]
11. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Scagliotti GV; Novello S
Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in advanced non-small cell lung cancer.
Govindan R
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
[TBL] [Abstract][Full Text] [Related]
13. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
16. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect.
Spiliotaki M; Markomanolaki H; Mela M; Mavroudis D; Georgoulias V; Agelaki S
Lung Cancer; 2011 Aug; 73(2):158-65. PubMed ID: 21190751
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced non-small-cell lung cancer in the elderly.
Gridelli C; Maione P; Rossi A; Ferrara ML; Castaldo V; Palazzolo G; Mazzeo N
Lung Cancer; 2009 Dec; 66(3):282-6. PubMed ID: 19879012
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
19. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]